MetaCap

Perspective Therapeutics (CATX) vs Journey Medical (DERM)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Journey Medical (DERM) has outperformed Perspective Therapeutics (CATX) over the past year, losing 55.8% versus a loss of 63.9%. Over five years, DERM leads with a -61.1% price change compared with -84.6% for CATX. Journey Medical is the larger company by market cap ($93.2 million vs $91.0 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

CATX-63.93%DERM-55.76%
+182%+53%-76%
Nov 21, 20251 yearNov 20, 2026
CATX-84.62%DERM-62.46%
+287%+91%-106%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

CATX versus DERM key metrics
MetricCATXDERM
Share price$0.7538$3.30
Market cap$91.03M$93.16M
1-day change-3.85%-7.04%
YTD return-72.59%-57.20%
1-year return-63.93%-55.76%
5-year return-84.62%-61.13%
EPS (TTM)$-1.25$-0.18
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$61.86M
Revenue growth (YoY)—+10.20%
Net income (latest FY)$-103.12M$-11.43M
Gross margin—66.17%
Operating margin—-13.21%
Net margin—-18.48%
52-week high$6.16$9.56
52-week low$0.73$3.21
Distance from 52-week high-87.76%-65.46%
Analyst consensusstrong_buystrong_buy
Avg. price target upside+1188.14%+286.36%
Average volume2.70M190.39K
Shares outstanding120.76M22.23M
Employees16358
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

About Perspective Therapeutics

CATX stock →

Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.

Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees

About Journey Medical

DERM stock →

Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.

Health Care · Biotechnology: Pharmaceutical Preparations · 58 employees

CATX vs DERM FAQ

Which is bigger, Perspective Therapeutics or Journey Medical?

Journey Medical (DERM) is larger, with a market capitalization of $93.16M compared with $91.03M for Perspective Therapeutics (CATX).

Which stock has performed better over the past year, CATX or DERM?

DERM returned -55.76% over the past 12 months, compared with -63.93% for CATX (price return, excluding dividends). Past performance does not predict future results.

Are Perspective Therapeutics and Journey Medical in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons